Semarion Ltd, a University of Cambridge spin-out company from the Cavendish Laboratory, combines materials engineering and cell biology to help biopharma companies make better medicines, faster. It announced today that it has closed a £2.14 million s
Funding will support recruitment, commercial partnerships, and further development of Semarion's SemaCyte cell assaying platform, which turns adherent cells into liquid reagents to enable novel